Semaglutide
Human RCTApproved medicineAlso known as: Ozempic, Wegovy, Rybelsus
Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.
Overview
A GLP-1 receptor agonist approved for type 2 diabetes and, at higher doses, chronic weight management. It is the best-evidenced peptide in this library, backed by large randomised trials.
Mechanism
Mimics glucagon-like peptide-1, enhancing glucose-dependent insulin secretion, slowing gastric emptying and reducing appetite via central pathways.
Evidence
Strong: multiple large phase 3 RCTs (SUSTAIN, STEP programmes) and regulatory approval.
Community-reported information
As a prescription medicine, dosing is set by the approved label and a clinician, typically titrated over weeks. This app does not restate a personalised schedule.
General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.
Half-life
~7 days (once-weekly dosing)
Storage
Refrigerate 2–8 °C; in-use pens per label.
Commonly reported side effects
- Nausea
- Vomiting
- Diarrhoea
- Constipation
- Injection-site reactions
Legal status by region
- USFDA-approved prescription medicine.
- GBMHRA-licensed; prescription only.
- AUTGA-registered; prescription only (Schedule 4).
Legal status changes over time; verify locally before relying on this.
Frequently asked questions
- Is semaglutide the same as Ozempic and Wegovy?
- Yes — they share the same active drug. Ozempic and Rybelsus are branded for type 2 diabetes and Wegovy for chronic weight management; the licensed dose and use differ by brand, which a prescriber decides.
- Is semaglutide legal to buy?
- It is a prescription-only medicine where licensed (US, UK, EU, Australia and beyond). 'Research' semaglutide bought outside that route is unregulated and, in many places, unlawful.
- How strong is the evidence for semaglutide?
- Very strong: it rests on large phase-3 randomised trials (the STEP and SUSTAIN programmes) and multiple regulatory approvals — the best-evidenced peptide in this library.